NanoEntek

Seoul, South Korea Founded: 2000 • Age: 26 yrs Listed
Point-of-care instruments for diagnostics and research are developed.

About NanoEntek

NanoEntek is a publicly listed company based in Seoul (South Korea) founded in 2000. Point-of-care instruments for diagnostics and research are developed. It operates in the Healthcare and Technology sectors. The company has 138 employees. Its website nanoentek.com draws about 14 thousand monthly visits. NanoEntek offers products and services including FREND™ System, EVE™ HT FL, ADAM™ MC Plus, ADAM™ rWBC HT, and ADAMII™. Its focus areas include High Tech, Nanotechnology, Nanoenabled Products and Life Science.

Company details

NanoEntek was founded in 2000 in Seoul, South Korea, where point-of-care instruments for in vitro diagnostics and life science research are developed. Proprietary MEMS fabrication technologies are utilized in flagship products. Automated immunoassay solutions like FREND and BUDDI, ADAM for rWBC counting, and the JULI series for cell counting are offered. Reagents and kits for oncology and infectious diseases are provided alongside these instruments.

  • Headquarters Seoul, South Korea
  • Employees 138
  • Stage Public
  • Sectors
    Healthcare
    Technology
  • Website category Health · Biotechnology and Pharmaceuticals
  • Website nanoentek.com
  • Social LinkedIn Facebook Instagram YouTube
  • Legal Name Nanoentek, Inc.
Key Metrics
  • Annual Revenue
    $26.4 M (USD)
    25.16
    as on Dec 31, 2025
  • Net Profit
    $1.09 M (USD)
    -55.93
    as on Dec 31, 2025
  • EBITDA
    $3.13 M (USD)
    37.76
    as on Dec 31, 2025
  • Latest Funding Round
    $8.43M (USD), Post-IPO

    Aug 2015

  • Employee Count
    138

Products & Services of NanoEntek

NanoEntek offers a comprehensive portfolio of products and services, including FREND™ System, EVE™ HT FL, ADAM™ MC Plus, ADAM™ rWBC HT, and ADAMII™.

FREND™ System
Immunofluorescence Analyzer

Device for rapid microfluidic immunofluorescence analysis.

EVE™ HT FL
Cell Counter

High-throughput fluorescence cell counting tool.

ADAM™ MC Plus
Cell Counter

Accurate fluorescence-based cell counting device.

ADAM™ rWBC HT
Cell Counter

Counter for residual white blood cell detection.

ADAMII™
Cell Counter

Fluorescence counter for CD34 cell analysis.

Apps and channels of NanoEntek

its YouTube channel NanoEntek 나노엔텍 has 365 subscribers and 30 videos.

NanoEntek 나노엔텍
YouTube 365 subscribers 30 videos Science & Technology
Open channel

Videos from NanoEntek

The most watched videos on NanoEntek's YouTube channel, NanoEntek 나노엔텍 (365 subscribers). Click a video to play it here.

The FREND System Introduction Video
6.4K views
FREND™ System Tutorial Video (Using AP System)
2.4K views
ADAMII-CD34 Tutorial Video
1.8K views
COVID-19 Product line up Introduction Video
1.5K views

More on NanoEntek 나노엔텍.

Funding Insights of NanoEntek

  • Total Rounds 1
  • Last Round Post-IPO — $8.43M
  • First Round $8.43M

    (Aug 2015)

All 1 funding rounds of NanoEntek with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Aug 2015$8.43MPost-IPO––
–

People of NanoEntek

5 people are tracked at NanoEntek (3 in leadership, 2 in team); the tracked headcount is 138.

NameRoleGroup
Chanil Chung
CEOLeadership
Sean Kim
본부장, Sr. Director Of Global SalesLeadership
Jun Young Seo
Chief Financial OfficerLeadership
Ashley Jamison
Western U.s. Territory Manager - Life ScienceTeam
Mino Kang
ManagerTeam
Premium access

Complete people profiles for NanoEntek

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of NanoEntek

NanoEntek is a publicly listed company on the KRX with ticker symbol 039860 in South Korea, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date15 Oct 2010
  • Listed onKRX: 039860
  • Listed entityNanoenTek, Inc.
  • Exchange sectorHealth technology
  • ISINKR7039860002
  • Share price4,290.00 KRW (-0.69% on the day) · 2026-10-14
  • Market capitalisation164,562,000,732.00 KRW
  • Price to earnings26.2
  • EPS (diluted, trailing year)163.63 KRW
  • Volume (last session)120,324

Financials of NanoEntek

Exchange-reported annual figures
YearRevenueNet incomeEBITDA
202538.13B KRW1.58B KRW4.52B KRW
202430.46B KRW3.59B KRW3.28B KRW
202326.84B KRW-3.68B KRW319.0M KRW
202235.20B KRW4.66B KRW6.82B KRW
202135.78B KRW7.32B KRW7.89B KRW
Premium access

Detailed financial statements for NanoEntek

Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.

  • Statement rows
  • Financial ratios
  • Five-year trends
  • Downloads

Verified entity values are shown only after access is granted.

Timeline of NanoEntek

3 dated milestones of NanoEntek across 15 years, from founding to its latest funding, stage changes and deals.

  1. Founded NanoEntek is founded.
  2. IPO Lists on the stock exchange (IPO).
  3. Funding First funding round of $8.4M.

Web traffic of NanoEntek

The website of NanoEntek (nanoentek.com) receives about 13.6K visits a month and ranks #1,579,171 among all websites worldwide, #2,113 in Biotechnology and Pharmaceuticals.

  • Monthly visits
    13.6K

    ▼ 11.4% vs previous month

  • Unique visitors
    7.4K

    per month

  • Global rank
    #1,579,171

    among all websites

  • Category rank
    #2,113

    Health · Biotechnology and Pharmaceuticals

Similar websites

Websites whose visitors overlap most with NanoEntek. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
meta-biomed.com
100%
12.9K#2,073,314View details
solco.co.kr
61%
View details
laxtha.com
laxtha.com
60%
#3,257,407–
inbody.com
inbody.com
60%
#73,580–
flukebiomedical.com
60%
#700,084View details
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
Premium access

All 9 similar websites and full traffic analytics for NanoEntek

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 9 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Nanoentek

Premium access

Complete news archive for NanoEntek

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about NanoEntek

NanoEntek was founded in 2000 and raised its 1st funding round 15 years after it was founded.

NanoEntek is headquartered in Seoul, South Korea.

NanoEntek has 138 employees.

Annual revenue of NanoEntek is $26.4M as on Dec 31, 2025.

NanoEntek was founded in 2000 in Seoul, South Korea, where point-of-care instruments for in vitro diagnostics and life science research are developed. Proprietary MEMS fabrication technologies are utilized in flagship products. Automated immunoassay solutions like FREND and BUDDI, ADAM for rWBC counting, and the JULI series for cell counting are offered. Reagents and kits for oncology and infectious diseases are provided alongside these instruments.

NanoEntek offers FREND™ System, EVE™ HT FL, ADAM™ MC Plus, ADAM™ rWBC HT, and ADAMII™.

Yes, NanoEntek is publicly traded on KRX under the ticker symbol 039860.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available